HomeCORT • NASDAQ
add
Corcept Therapeutics Inc
Previous close
$87.13
Year range
$49.00 - $117.33
Market cap
9.17B USD
Avg Volume
707.05K
P/E ratio
98.36
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 207.64M | 13.75% |
Operating expense | 192.82M | 44.89% |
Net income | 19.67M | -58.34% |
Net profit margin | 9.47 | -63.38% |
Earnings per share | 0.16 | -60.98% |
EBITDA | 10.51M | -77.60% |
Effective tax rate | -29.03% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 421.68M | 10.87% |
Total assets | 823.61M | 5.02% |
Total liabilities | 191.70M | 31.83% |
Total equity | 631.90M | — |
Shares outstanding | 105.19M | — |
Price to book | 14.50 | — |
Return on assets | 3.14% | — |
Return on capital | 3.99% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 19.67M | -58.34% |
Cash from operations | 54.48M | -25.67% |
Cash from investing | 14.64M | 133.26% |
Cash from financing | -46.41M | -120.05% |
Net change in cash | 22.39M | 157.36% |
Free cash flow | 38.75M | -44.81% |
About
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
Founded
May 13, 1998
Headquarters
Website
Employees
500
